<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02839291</url>
  </required_header>
  <id_info>
    <org_study_id>P/2015/279</org_study_id>
    <nct_id>NCT02839291</nct_id>
  </id_info>
  <brief_title>Evaluation of Medical Practice in the Management of Bone Metastases After Injectable Bone Antiresorptive Treatment, and Its Influence on Quality of Life</brief_title>
  <acronym>PRISM</acronym>
  <official_title>Evaluation of Medical Practice in the Management of Bone Metastases After Injectable Bone Antiresorptive Treatment, and Its Influence on Quality of Life</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Besancon</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Besancon</source>
  <brief_summary>
    <textblock>
      To evaluate the current medical practice and its influence on health-related quality of life,
      in patients who are treated with injectable bone antiresorptive drugs (biphosphonates or
      denosumab) for at least one year.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This protocol will evaluate the pursuit of injectable bone antiresorptive treatments or their
      switch to oral biphosphonates, or treatment stop, in the contexte of medical practice.

      The primary end-point is the health-related quality of life (QoL). Secondary endpoints are
      safety, overall survial, the impact of toxicities of the treatment on QoL, and the
      description of supportive care.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">May 2021</completion_date>
  <primary_completion_date type="Anticipated">November 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>evaluation of 4 targeted dimensions of the EORTC-QLQ-BM22 quality of life questionarie</measure>
    <time_frame>to 6 months</time_frame>
    <description>evaluation of 4 parameters: painful sites characteristics of pain, functional impairment, psychosocial aspect</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Tumor With Bone Metastasis</condition>
  <arm_group>
    <arm_group_label>quality of life questionaries</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients should complete 3 quality of life questionaries (EORTC-QLQ C30 ; EORTC QLQ-BM22 and Euroqol EQ-5D) at many time points : at inclusion, every 3 months and at the end of study visit (2 years after inclusion)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>quality of life questionaries</intervention_name>
    <arm_group_label>quality of life questionaries</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>intravenous or oral bone antiresorptive treatments</intervention_name>
    <arm_group_label>quality of life questionaries</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient with histologically proven tumor with bone metastasis, single or multiple
             (with or without metastasis extra-osseous)

          -  Patients treated with injectable bone antiresorptive therapy for 12 months or more

          -  Signed written informed consent

        Exclusion Criteria:

          -  patient with any medical or psychiatric condition or disease which would make the
             patient inappropriate to complete quality of life questionaries

          -  patient under guardianship, curator or under the protection of justice, pregnant or
             breast-feeding women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stefano KIM, Dr</last_name>
    <email>stefanokim@me.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Centre Hospitalier Régional Universitaire de Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano KIM, Dr</last_name>
      <email>stefanokim@me.com</email>
    </contact>
    <investigator>
      <last_name>Stefano KIM, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord Franche-Comté</name>
      <address>
        <city>Montbéliard</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefano KIM, Dr</last_name>
      <email>stefanokim@me.com</email>
    </contact>
    <investigator>
      <last_name>Stefano KIM, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 18, 2016</study_first_submitted>
  <study_first_submitted_qc>July 18, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2016</study_first_posted>
  <last_update_submitted>July 20, 2016</last_update_submitted>
  <last_update_submitted_qc>July 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 21, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Bone Neoplasms</mesh_term>
    <mesh_term>Bone Marrow Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

